Parkinson Disease, Idiopathic
Conditions
Keywords
Parkinson Disease, Strength training, Endurance training, Physiotherapy, Irisin, Quality of Life, Physical performance
Brief summary
The goal of this clinical trial is to determine whether adding strength training to aerobic training has a comparable or greater effect on the clinical status of Parkinson's disease patients than a standalone aerobic training. \- Does combined strength-endurance circuit training provide added benefits to physical performance, disease severity, blood biomarkers, and quality of life in PD patients compared to standalone aerobic training? Participants will: * undergo outcome measurements before and after the 12-week intervention and a 3-month follow-up measurement, * visit the clinic twice a week for 1-hour training sessions. * selected patients will be given a smartwatch with a pedometer that will count their average number of steps before, during and after the training period
Interventions
OTHERStrength-Endurance Training
The intervention for the experimental Strength-Endurance group includes warm-up, three laps of strength and endurance exercises and cool-down. The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions.
OTHEREndurance Training
The intervention for the control Endurance training group includes warm-up, three laps of endurance exercises and cool-down. The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions.
Sponsors
General University Hospital, Prague
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* age ≥18 years * diagnosis of idiopathic Parkinson´s disease * Hoehn-Yahr Scale ≤ 2,5 * stable dopaminergic medication
Exclusion criteria
* age ≥75 years * Hoehn-Yahr Scale ≥ 2,5 * deep brain stimulation * presence of freezing * Camptocormia * inability to walk without support * inability to perform study procedures * limiting co-morbidities * attendance at training sessions below 70%
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II. and III. | From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up) | The maximum total UPDRS score is 272, indicating the worst possible disability from PD. The minimum total score is 0, indicating no disability from PD. Improvement greater than (-4.9) points or worsening more than (+4.2) points on MDS-UPDRS II+III represent a minimal clinically important difference. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Timed Up and Go Test (TUG) | From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up) | Mean TUG score for Non-falling PD patients on medication is 7.94 (2.15) seconds. MCID is 3.5 seconds. |
| Blood irisin levels | From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up) | — |
| Cardiopulmonary Exercise Testing | From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up) | — |
| One Repetition Maximum (1RM) | From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up) | One Repetition Maximum in strength training is the maximum weight that can be lifted once while maintaining the correct lifting technique. It will be measured using a leg press machine for the lower extremities and a dumbbell chest press for the upper extremities. |
| Blood brain-derived neurotrophic factor levels | From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up) | — |
| Blood cytokine levels | From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up) | — |
| Average number of steps | Average number of steps in the period before training (6 months), during the training period (3 months), period after training (3 months). | — |
| The Parkinson's Disease Questionnaire (PDQ-39) | From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up) | The minimum score is 0, while the maximum score is 100. A higher score indicates a lower QoL. |
Countries
Czechia
Contacts
Primary ContactJakub Vítek, MSc.
Outcome results
None listed